Currently, there are 111.43M common shares owned by the public and among those 107.97M shares have been available to trade.
The company’s stock has a 5-day price change of -20.22% and -48.47% over the past three months. VKTX shares are trading -15.68% year to date (YTD), with the 12-month market performance up to 61.34% higher. It has a 12-month low price of $20.28 and touched a high of $99.41 over the same period. VKTX has an average intraday trading volume of 4.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.48%, -32.38%, and -43.15% respectively.
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 73.77% of the company’s 111.43M shares outstanding.
It has a market capitalization of $3.78B and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.22% over the week and 5.67% over the month.
Analysts forecast that Viking Therapeutics Inc (VKTX) will achieve an EPS of -0.27 for the current quarter, -0.28 for the next quarter and -1.42 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.34 while analysts give the company a high EPS estimate of -0.34. Comparatively, EPS for the current quarter was -0.25 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.65%, and -56.39% over the next financial year.
B. Riley Securities coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on November 22, 2024 offered a Buy rating with a price target of $109. H.C. Wainwright was of a view on November 04, 2024 that the stock is Buy, while JP Morgan gave the stock Overweight rating on September 11, 2024, issuing a price target of $80. Morgan Stanley on their part issued Overweight rating on June 27, 2024.
